Venrock Adviser, LLC

Position in ERAS — Erasca, Inc.

CIK 1615982 NEW YORK, NY

Position in ERAS

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$265,073,898

+$198,645,550 QoQ

Shares Held

16,382,812

-8.3% QoQ

Ownership

5.27%

of shares outstanding

% of Portfolio

9.89%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2024

8 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

Venrock Adviser, LLC holds $2,679,121,844 across 33 Biotechnology names. ERAS ranks #2 (9.9% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	APGE	Apogee Therapeutics, Inc.	8,493,321	$714,882,828
2	ERAS	Erasca, Inc. This page	16,382,812	$265,073,898
3	ORKA	Oruka Therapeutics, Inc.	4,148,428	$203,480,393
4	SYRE	Spyre Therapeutics, Inc.	3,685,448	$185,893,997
5	KALV	KalVista Pharmaceuticals, Inc.	6,474,485	$130,331,383
6	DNTH	Dianthus Therapeutics, Inc. /DE/	1,180,000	$99,025,600
7	DMRA	Damora Therapeutics, Inc.	3,603,595	$93,333,110
8	OCUL	Ocular Therapeutix, Inc	10,346,926	$87,638,463

8 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$265,073,898	16,382,812	-8.3%	Shares	Sole	2026-05-15
2025-12-31	$66,428,348	17,857,083	0.0%	Shares	Sole	2026-02-17
2025-09-30	$38,928,440	17,857,083	0.0%	Shares	Sole	2025-11-14
2025-06-30	$22,678,495	17,857,083	+10.1%	Shares	Sole	2025-08-14
2025-03-31	$22,216,215	16,216,216	0.0%	Shares	Sole	2025-05-15
2024-12-31	$40,702,702	16,216,216	0.0%	Shares	Sole	2025-02-14
2024-09-30	$44,270,269	16,216,216	0.0%	Shares	Sole	2024-11-14
2024-06-30	$38,270,269	16,216,216	—	Shares	Sole	2024-08-14
No filing history on record for this holder in this stock.